US3287375A - Nu, nu-dimethyl-nu-(2, 3-epoxypropyl)-omicron-substituted benzylammonium salts - Google Patents

Nu, nu-dimethyl-nu-(2, 3-epoxypropyl)-omicron-substituted benzylammonium salts Download PDF

Info

Publication number
US3287375A
US3287375A US380671A US38067164A US3287375A US 3287375 A US3287375 A US 3287375A US 380671 A US380671 A US 380671A US 38067164 A US38067164 A US 38067164A US 3287375 A US3287375 A US 3287375A
Authority
US
United States
Prior art keywords
epoxypropyl
methyl
mole
dimethyl
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US380671A
Inventor
Mcgregor Donald Neil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Priority to US380671A priority Critical patent/US3287375A/en
Application granted granted Critical
Publication of US3287375A publication Critical patent/US3287375A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/36Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D331/00Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom
    • C07D331/02Three-membered rings

Definitions

  • This invention relates to certain quaternary amines of therapeutic value in the treatment of depression and more particularly to N,N-dimethyl-N-(2,3-epoxypropyl)-o-substituted benzylarnmonium salts and N,N-dimethyl-N- (2,3-epithiopropyl)-o-substituted benzylarnmonium salts. It is the object of the present invention to provide chemical compounds which Will serve to counteract psychic depression without stimulating motor activity or appearing to stimulate the central nervous system.
  • R is selected from the group consisting of fluoro, chloro, bromo, iodo and lower alkyl, R is sulfur or oxygen but preferably oxygen, and X represents one equivalent of a nontoxic anion.
  • lower alkyl as used in the specification and claims includes radicals containing one to six carbon atoms inclusive, e.g. methyl, ethyl, n-propyl, isopropyl, isobutyl, n-amyl, n-hexyl, isohexyl, Z-ethylbutyl, and the like.
  • the preferred nontoxic anions represented by X above include the halides (chloride, bromide and iodide), lower alkyl sulfates and the alkyl and aryl sulfonates. Each of these anions is bound by ionic linkage with the positively charged nitrogen atoms.
  • the anion X is of little consequence in such active compounds since the physiological activity resides in the cation.
  • X may be chloride, bromide, iodide, methanesulfonate, ethanesulfonate, toluenesulfonate or the like. By exchange reactions one of the original variants of X might be re placed by maleate, succinate, fumarate, tartrate or oleate.
  • the compounds of the present invention are useful in the treatment of psychic depression.
  • N,N dimethyl (o-chlorobenzyl)-N-(2,3-epoxypropyl)- ammonium iodide administered at doses as low as 10 mgm./ kg. p.o. in the mouse given prior to treatment with mgm./ kg. reserpine caused the mice to behave normally and prevented the usual sedative effect of reserpine.
  • This is a marked contrast to the results of pretreatment with monoamine oxidase inhibitors before reserpine dosage, as in that instance the mice exhibit great motor stimulation and indeed become so hyperactive that death usually results.
  • mice The oral lethal dose for fifty percent (50%) of the mice was found to be 1780 mgm./kg. of body weight.
  • the compounds of the present invention exhibit marked antidepressant activity Without the motor stimulation of the usual monoamine oxidase inhibitors.
  • the ortho-fiuorobenzyl and the ortho-methylbenzyl compounds of the present invention had exhibited reserpine reversal at doses as low as 50 and 40 mgm./kg. p.o. respectively.
  • the compounds of the present invention are prepared by reacting epichlorohydn'n with an N-methyl ort-hosubstituted benzylamine followed by reaction with sodium hydroxide to obtain a tertiary amine reaction product and then quaternizing the amine with an alkylating agent having the general formula CH X where X is any therapeutically acceptable anion. If desirable, X may then be replaced with any other therapeutically acceptable anion through ion exchange reactions known in the art.
  • the secondary amines used as starting agents in the preparation of the compounds of the present invention may be prepared from the appropriate substituted benzaldehyde by reaction with methylamine and reduction of the reaction product to the secondary amine.
  • Such procedures are reported in The Preparation of Amines by Reductive A'lkylation by W. S. Emerson, Organic Reactions, vol. 4, p. 174, John Wiley & Sons, Inc., 1948 and in I. H. Billman and A. C. Diesing, J. Org. Chem., 22, 1068 (1957) and may be illustrated by the following equations, using o-chlorobenzaldehyde for the preparation of N-methyl-o-chlorobenzylamine:
  • the appropriately substituted benzoic acid chloride or equivalent may be reacted with methylamine to obtain an N-methyl amide which may be treated with a reducing agent such as lithium aluminum hydride to give the desired N-methyl-o-substituted benzylamine.
  • a reducing agent such as lithium aluminum hydride
  • quaternary ammonium salts are useful as pharmaceuticals. More specifically, compounds of this invention are antidepressants which are not monoamine oxidase inhibitors.
  • N,N-dimethyl-N-(2,3-epoxypropyl)-N-benzylammonium salts substituted at the ortho position with bromine, iodine or a lower-alkyl radical may be prepared by substituting the appropriate secondary amine as a reagent in the procedure of Examples 1 through 3.
  • the compounds of the present invention may be synthesized by reaction of N-(2,3-epoxypropyl)-dimethylamine with an appropriately o-substituted benzyl halide, etc. or by the reaction of a methyl halide, etc. with an appropriately o-substituted N-benzyl-N-2,3-epoxypropyl- N-methylamine.
  • the 2,3-epithiopropy-l substituted compounds may be prepared instead of the preferred epoxypropyl compounds by the addition of the following step to the procedure of Examples 1 through 4, to wit, after the preparation of the tertiary amine and before quaternization, the tertiary amine is reacted with potassium thiocyanate and methanol to give the desired N-methyl-N-(2,3-epithiopropyl)-o-sub stituted benzylamine which is then quaterm'zed to the desired salt.
  • Example 1 N-methyl-o-chlorobenzylamine (15.56 g., 0.1 mole) and 0.3 ml. of water was added to epichlorohydrin (9.25 g., 0.1 mole) dropwise with stirring and cooling (ice bath). The mixture was stirred overnight in the melting ice bath. The mixture was then cooled in ice and a cold solution of sodium hydroxide (4.8 g., 0.12 mole) in 8 ml. of water was adder over 15 minutes with stirring. After the addition was complete, the ice bath was removed and stirring was continued at room tempearture for 20 minutes. The resulting mixture was then added to 25 ml. of water and extracted with five 50-ml. portions of ether.
  • epichlorohydrin 9.25 g., 0.1 mole
  • the quaternary ammonim iodide salt was then prepared by adding methyl iodide (11.4 g., 0.081 mole) dropwise to a stirred, cooled (ice bath) solution of N-methyl-N-(2,3-epoxypropyl)-o-chlor-obenzylamine (9.0 g., 0.051 mole) in 30 ml. of acetonitrile. After the addition was complete, the ice bath was removed and the mixture was stored at 25 C. for eight hours. The mixture was then poured into 100 ml. of ether and kept overnight at 5 C. An oil resulted which was separatcd from the ether and dried in high vacuum. It crystailized after four days.
  • Example 2 N-methyl-o-fiuorobenzylamine (13.9 g., 0.1 mole) and 0.3 ml. of water was added slowly over a period of minutes to mechanically stirred, cooled epichlorohydrin (9.25 g., 0.1 mole). The entire mixture was stirred overnight in a melting ice bath. The mixture was then cooled in ice and with mechanical stirring, a cold solution of sodium hydroxide (4.8 g., 0.12 mole), in 8 ml. of Water was added dropwise over a period of 15 minutes. Then the ice bath was removed and the mixture was stirred for an additional minutes. The mixture was then added to ml. of water and extracted three times with 100-ml. portions of ether.
  • sodium hydroxide 4.8 g., 0.12 mole
  • Methyl iodide (6.38 g., 0.045 mole) was added slowly to a magnetically stirred cooled solution of N-methyl-N-(2,3-epoxypropyl)-o-fluorobenzylamine (6.51 g., 0.02 mole) in 30 m1. of acetonitrile. The ice bath was removed and the solution was stirred for three hours at room temperature. Ether was then added to thesolution until it became cloudy and the entire mixture was kept overnight at 5 C. The crystals were removed by filtration and dried under reduced pressure yielding N,N-dimethyl-N-(2,3-epoxypropyD-N-(ofluorobenzyD-ammonium iodide, 5.0 g.
  • Example 3 N-methyl-o-methylbenzylamine (20.0 g., 0.15 mole) and 0.45 ml. of water was added slowly to epichlorohydrin (13.87 g., 0.15 mole) with stirring and cooling (ice bath). The mixture was stirred in the melting ice bath overnight. The mixture was then cooled in ice and a cold solution of sodium hydroxide (7.2 g., 0.18 mole) in 12 ml. of Water was added slowly. After the addition was complete, the ice bath was removed and stirring was continued for an additional 20 minutes. The resulting mixture was then added to 37.5 ml. of water and extracted with three 100-ml. portions of ether.
  • the quaternary ammonium-p-toluenesulfonate salt was then prepared by slowly adding methyl-p-toluenesultonate (4.65 g., 0.025 mole) to a stirred cooled (ice bath) solution of N-rnethyl-N-(2,3-epoxypropyl)-omethylbenzylamine (4.55 g., 0.025 mole in 25 ml. of acetonitrile. The ice bath was removed and the solution was stirred for three hours. Ether was added until the cloudpoint was reached and the mixture was kept overnight at 4 C. Crystals resulted which were removed by filtration and dried under reduced pressure.
  • Example 4 A mixture of N-rnethyl-N-(2,3-epoxypropyl)-0-chlorobenzyla rnine (31.75 g., 0.15 mole) and potassium thiocyanate (21.86 g., 0.225 mole) in 75 ml. of methanol was refluxed for one hour. The mixture was then cooled to 25 C., added to 200 ml. of water and extracted three times with 100 ml. portions of ether. The ether extracts were combined, dried over sodium sulfate, filtered and concentrated to an oil which was distilled at 0.05 mm. Hg, yielding 11.5 g. of N-methyl-N-(2,3-epithiopropyl)-'ochlorobenzylamine, Bl 94 C.
  • a quaternary ammonium salt having the formula (IJHa OH2NZ6OH2CHCH2 R1 Xe wherein R is a member selected from the group consisting of fiuoro, chloro, bromo, iodo and lower alkyl and X is a therapeutically acceptable anion.
  • a quaternary ammonium salt having the formula wherein X is a therapeutically acceptable anion.
  • a quaternary ammonium salt having the formula 1 CH-NGH -CHCH1 X CH CH1 wherein X is a therapeutically acceptable anion.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

United States Patent 3,287,375 N,N-DIMETHYL-N-(2,3-EPOXYPROPYL)-o-SUBSTI- TUTED BENZYLAMMONIUM SALTS Donald Neil McGrcgor, Syracuse, N.Y., assignor to Bristol-Myers Company, New York, N.Y., a corporation of Delaware No Drawing. Filed July 6, 1964, Ser. No. 380,671 6 Claims. (Cl. 260-348) This invention relates to certain quaternary amines of therapeutic value in the treatment of depression and more particularly to N,N-dimethyl-N-(2,3-epoxypropyl)-o-substituted benzylarnmonium salts and N,N-dimethyl-N- (2,3-epithiopropyl)-o-substituted benzylarnmonium salts. It is the object of the present invention to provide chemical compounds which Will serve to counteract psychic depression without stimulating motor activity or appearing to stimulate the central nervous system.
There is provided by the present invention a compound selected from the group having the formula in X9 wherein R is selected from the group consisting of fluoro, chloro, bromo, iodo and lower alkyl, R is sulfur or oxygen but preferably oxygen, and X represents one equivalent of a nontoxic anion.
The term lower alkyl as used in the specification and claims includes radicals containing one to six carbon atoms inclusive, e.g. methyl, ethyl, n-propyl, isopropyl, isobutyl, n-amyl, n-hexyl, isohexyl, Z-ethylbutyl, and the like.
The preferred nontoxic anions represented by X above include the halides (chloride, bromide and iodide), lower alkyl sulfates and the alkyl and aryl sulfonates. Each of these anions is bound by ionic linkage with the positively charged nitrogen atoms. The anion X is of little consequence in such active compounds since the physiological activity resides in the cation. As prepared, X may be chloride, bromide, iodide, methanesulfonate, ethanesulfonate, toluenesulfonate or the like. By exchange reactions one of the original variants of X might be re placed by maleate, succinate, fumarate, tartrate or oleate. The salts obtained through these variations of X may in some cases have special advantages due to solubility, ease of crystallization, lack of objectionable taste, etc, but these are all subsidiary to the main physiological action which is independent of the character of X Hence, all variants of X are considered equivalents.
The compounds of the present invention are useful in the treatment of psychic depression. For example, N,N dimethyl (o-chlorobenzyl)-N-(2,3-epoxypropyl)- ammonium iodide administered at doses as low as 10 mgm./ kg. p.o. in the mouse given prior to treatment with mgm./ kg. reserpine caused the mice to behave normally and prevented the usual sedative effect of reserpine. This is a marked contrast to the results of pretreatment with monoamine oxidase inhibitors before reserpine dosage, as in that instance the mice exhibit great motor stimulation and indeed become so hyperactive that death usually results. The oral lethal dose for fifty percent (50%) of the mice was found to be 1780 mgm./kg. of body weight. Thus the compounds of the present invention exhibit marked antidepressant activity Without the motor stimulation of the usual monoamine oxidase inhibitors. By way of further illustration, the ortho-fiuorobenzyl and the ortho-methylbenzyl compounds of the present invention had exhibited reserpine reversal at doses as low as 50 and 40 mgm./kg. p.o. respectively.
"ice
The compounds of the present invention are prepared by reacting epichlorohydn'n with an N-methyl ort-hosubstituted benzylamine followed by reaction with sodium hydroxide to obtain a tertiary amine reaction product and then quaternizing the amine with an alkylating agent having the general formula CH X where X is any therapeutically acceptable anion. If desirable, X may then be replaced with any other therapeutically acceptable anion through ion exchange reactions known in the art.
The secondary amines used as starting agents in the preparation of the compounds of the present invention may be prepared from the appropriate substituted benzaldehyde by reaction with methylamine and reduction of the reaction product to the secondary amine. Such procedures are reported in The Preparation of Amines by Reductive A'lkylation by W. S. Emerson, Organic Reactions, vol. 4, p. 174, John Wiley & Sons, Inc., 1948 and in I. H. Billman and A. C. Diesing, J. Org. Chem., 22, 1068 (1957) and may be illustrated by the following equations, using o-chlorobenzaldehyde for the preparation of N-methyl-o-chlorobenzylamine:
Alternately, the appropriately substituted benzoic acid chloride or equivalent may be reacted with methylamine to obtain an N-methyl amide which may be treated with a reducing agent such as lithium aluminum hydride to give the desired N-methyl-o-substituted benzylamine. This procedure is reported in Reductions by Lithium Aluminum Hydride by W. G. Brown in Organic Reactions, vol. 6, p. 469, John Wiley & Sons, Inc., 1951.
The preparation of the compounds of the present invention may be illustrated by the following equations using epichlorohydrin and o-chloro-N-methylbenzylamine and methyl iodide as the reagents for illustrative purposes:
The resulting quaternary ammonium salts are useful as pharmaceuticals. More specifically, compounds of this invention are antidepressants which are not monoamine oxidase inhibitors.
The N,N-dimethyl-N-(2,3-epoxypropyl)-N-benzylammonium salts substituted at the ortho position with bromine, iodine or a lower-alkyl radical may be prepared by substituting the appropriate secondary amine as a reagent in the procedure of Examples 1 through 3.
The compounds of the present invention may be synthesized by reaction of N-(2,3-epoxypropyl)-dimethylamine with an appropriately o-substituted benzyl halide, etc. or by the reaction of a methyl halide, etc. with an appropriately o-substituted N-benzyl-N-2,3-epoxypropyl- N-methylamine.
- The 2,3-epithiopropy-l substituted compounds may be prepared instead of the preferred epoxypropyl compounds by the addition of the following step to the procedure of Examples 1 through 4, to wit, after the preparation of the tertiary amine and before quaternization, the tertiary amine is reacted with potassium thiocyanate and methanol to give the desired N-methyl-N-(2,3-epithiopropyl)-o-sub stituted benzylamine which is then quaterm'zed to the desired salt.
The following examples are given to illustrate the scope of this invention without limiting it thereto.
Example 1 N-methyl-o-chlorobenzylamine (15.56 g., 0.1 mole) and 0.3 ml. of water was added to epichlorohydrin (9.25 g., 0.1 mole) dropwise with stirring and cooling (ice bath). The mixture was stirred overnight in the melting ice bath. The mixture was then cooled in ice and a cold solution of sodium hydroxide (4.8 g., 0.12 mole) in 8 ml. of water was adder over 15 minutes with stirring. After the addition was complete, the ice bath was removed and stirring was continued at room tempearture for 20 minutes. The resulting mixture was then added to 25 ml. of water and extracted with five 50-ml. portions of ether. The combined ether extracts were then dried over anhydrous sodium sulfate, filtered and concentrated to a light yellow oil. Distillation of this oil at 0.1 mm. Hg, main fraction distilling at 71-72 C. yielded 9.03 g. of N-methyl-N-(2,3-epoxypropyl)-o-chlorobenzylamine as an oil. The quaternary ammonim iodide salt was then prepared by adding methyl iodide (11.4 g., 0.081 mole) dropwise to a stirred, cooled (ice bath) solution of N-methyl-N-(2,3-epoxypropyl)-o-chlor-obenzylamine (9.0 g., 0.051 mole) in 30 ml. of acetonitrile. After the addition was complete, the ice bath was removed and the mixture was stored at 25 C. for eight hours. The mixture was then poured into 100 ml. of ether and kept overnight at 5 C. An oil resulted which was separatcd from the ether and dried in high vacuum. It crystailized after four days. It was triturated with ether and dried in high vacuum yielding N,N-dimethyl-N-(o-chlorobenzyl)-N-(2,3cpoxypropyl)-ammonium iodide, 4.88 g., M.P. 95 C.
Analysis.Calculated for C H NOCII: C, 40.75; H, 4.85; N, 3.96. Found: C, 41.00; H, 5.02; N, 3.99.
Example 2 N-methyl-o-fiuorobenzylamine (13.9 g., 0.1 mole) and 0.3 ml. of water was added slowly over a period of minutes to mechanically stirred, cooled epichlorohydrin (9.25 g., 0.1 mole). The entire mixture was stirred overnight in a melting ice bath. The mixture was then cooled in ice and with mechanical stirring, a cold solution of sodium hydroxide (4.8 g., 0.12 mole), in 8 ml. of Water was added dropwise over a period of 15 minutes. Then the ice bath was removed and the mixture was stirred for an additional minutes. The mixture was then added to ml. of water and extracted three times with 100-ml. portions of ether. The ether extracts were combined, dried over anhydrous sodium sulfate, filtered and concentrated to an oil. The oil was then distilled at 0.3 mm. Hg, the main fraction distilling at 65 C. The oil was distilled again at 0.025 mm. Hg, the main fraction distilling at 45.5 C. yielding 7251 g. of N-rnethyl-N-(2,3-epoxypropyl)-o-fluorobenzylamine as an oil. Methyl iodide (6.38 g., 0.045 mole) was added slowly to a magnetically stirred cooled solution of N-methyl-N-(2,3-epoxypropyl)-o-fluorobenzylamine (6.51 g., 0.02 mole) in 30 m1. of acetonitrile. The ice bath was removed and the solution was stirred for three hours at room temperature. Ether was then added to thesolution until it became cloudy and the entire mixture was kept overnight at 5 C. The crystals were removed by filtration and dried under reduced pressure yielding N,N-dimethyl-N-(2,3-epoxypropyD-N-(ofluorobenzyD-ammonium iodide, 5.0 g.
Analysis.Calculated for C H NOFI: C, 42.85; H, 5.16; N, 4.16. Found: C, 42.30; H, 5.20; N, 3.94.
Example 3 N-methyl-o-methylbenzylamine (20.0 g., 0.15 mole) and 0.45 ml. of water was added slowly to epichlorohydrin (13.87 g., 0.15 mole) with stirring and cooling (ice bath). The mixture was stirred in the melting ice bath overnight. The mixture was then cooled in ice and a cold solution of sodium hydroxide (7.2 g., 0.18 mole) in 12 ml. of Water was added slowly. After the addition was complete, the ice bath was removed and stirring was continued for an additional 20 minutes. The resulting mixture was then added to 37.5 ml. of water and extracted with three 100-ml. portions of ether. The ether extracts were combine-d, dried over anhydrous sodium sulfate, filtered and concentrated to an oil. Distillation of this oil at 0.05 mm. Hg, yielded 8.43 g. of N-methyl-N-(2,3 epoxypropyl)-o-methylbenzylamine distilling at 73 C. as an oil. The quaternary ammonium-p-toluenesulfonate salt was then prepared by slowly adding methyl-p-toluenesultonate (4.65 g., 0.025 mole) to a stirred cooled (ice bath) solution of N-rnethyl-N-(2,3-epoxypropyl)-omethylbenzylamine (4.55 g., 0.025 mole in 25 ml. of acetonitrile. The ice bath was removed and the solution was stirred for three hours. Ether was added until the cloudpoint was reached and the mixture was kept overnight at 4 C. Crystals resulted which were removed by filtration and dried under reduced pressure. Recrystallization from ace-tonitrile-ether yielded 1.7 g. of N-methyl-N-(2,3- epoxypropyl)-o-rnethylbenzylammonium p-toluenesulfonate, M.P. 109 C.
Analysis.Calculated for C H NO S: C, 63.63; H, 7.21; N. 3.72. Found: C, 63.40; H, 7.33; N, 3.72.
Example 4 A mixture of N-rnethyl-N-(2,3-epoxypropyl)-0-chlorobenzyla rnine (31.75 g., 0.15 mole) and potassium thiocyanate (21.86 g., 0.225 mole) in 75 ml. of methanol was refluxed for one hour. The mixture was then cooled to 25 C., added to 200 ml. of water and extracted three times with 100 ml. portions of ether. The ether extracts were combined, dried over sodium sulfate, filtered and concentrated to an oil which was distilled at 0.05 mm. Hg, yielding 11.5 g. of N-methyl-N-(2,3-epithiopropyl)-'ochlorobenzylamine, Bl 94 C.
Analysis.Ca'lculated for C H NSCI: C, 58.00; H, 6.19; N, 6.15; S, 14.08; Cl, 15.57. Found: C, 58.25; H, 6.23; N, 6.59; S, 13.60; Cl, 15.58.
To N methyl-N-(2,3-epithiopropyl)-o-chlorobenzylamine (9.99 g., 0.044 mole) in 40 ml. of freshly distilled acetonitrile was added p-methyltoluene sulfonate (9.87 g., 0.053 mole). The mixture was allowed to stand at 25 C. for two hours. Ether was then added to the mixture until crystallization began and it was kept at 25 C. for 24 hours and then at 4 C. for 24 hours. The crystals were removed by filtration, dried under reduced pressure and recrystallized from ethanol yielding N,N-dimethyl-N-(2,3- epithiopropyl)-N-o-chlorobenzylammonium p-toluene sulfonate, M.P. 109-192 C.
Analysis-Calculated for C H NO S Cl: C, 55.12; H, 5.84; N, 3.38. Found: C, 55.25; H, 5.82; N, 3.37.
7 What I claim is: 1. A quaternary ammonium salt having the formula (IJHa OH2NZ6OH2CHCH2 R1 Xe wherein R is a member selected from the group consisting of fiuoro, chloro, bromo, iodo and lower alkyl and X is a therapeutically acceptable anion.
2. A quaternary ammonium salt having the formula wherein X is a therapeutically acceptable anion.
3. A quaternary ammonium salt having the formula wherein X is a therapeutically acceptable anion.
4. A quaternary ammonium salt having the formula wherein X is a therapeutically acceptable anion.
6 5, A quaternary ammonium salt having the formula l CHrNCHgCHCHz X F CH3 wherein X is a therapeutically acceptable anion.
6. A quaternary ammonium salt having the formula 1 CH-NGH -CHCH1 X CH CH1 wherein X is a therapeutically acceptable anion.
References Cited by the Applicant UNITED STATES PATENTS 1,790,042 1/ 1931 Eisleb. 2,605,286 7/1952 Melarned. 2,876,217 3/1959 Paschall.
JULIAN S. LEVITT, Primary Examiner.
SAM ROSEN, Examiner.
S. J. FRIEDMAN, Assistant Examiner.

Claims (1)

1. A QUATERNARY AMMONIUM SALT HAVING THE FORMULA
US380671A 1964-07-06 1964-07-06 Nu, nu-dimethyl-nu-(2, 3-epoxypropyl)-omicron-substituted benzylammonium salts Expired - Lifetime US3287375A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US380671A US3287375A (en) 1964-07-06 1964-07-06 Nu, nu-dimethyl-nu-(2, 3-epoxypropyl)-omicron-substituted benzylammonium salts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US380671A US3287375A (en) 1964-07-06 1964-07-06 Nu, nu-dimethyl-nu-(2, 3-epoxypropyl)-omicron-substituted benzylammonium salts

Publications (1)

Publication Number Publication Date
US3287375A true US3287375A (en) 1966-11-22

Family

ID=23502050

Family Applications (1)

Application Number Title Priority Date Filing Date
US380671A Expired - Lifetime US3287375A (en) 1964-07-06 1964-07-06 Nu, nu-dimethyl-nu-(2, 3-epoxypropyl)-omicron-substituted benzylammonium salts

Country Status (1)

Country Link
US (1) US3287375A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3336196A (en) * 1964-07-06 1967-08-15 Bristol Myers Co Antidepressant compositions
US3366609A (en) * 1964-09-12 1968-01-30 Dunlop Rubber Co Polymerization of episulfides
US3475458A (en) * 1967-08-11 1969-10-28 Shell Oil Co Production of epoxy ammonium salts
WO1983000513A1 (en) * 1981-08-10 1983-02-17 Saingier, Jean New n-oxyranemethane n,n,n-trialkylammonium derivatives, preparation method and utilization thereof for the treatment of polyhydroxylated and polyamnated polymers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1790042A (en) * 1926-08-03 1931-01-27 Winthrop Chem Co Substituted 1, 3-di-amino-2-propanols
US2605286A (en) * 1951-01-04 1952-07-29 Rohm & Haas Acetonyl alkylbenzyl dialkyl ammonium salts
US2876217A (en) * 1956-12-31 1959-03-03 Corn Products Co Starch ethers containing nitrogen and process for making the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1790042A (en) * 1926-08-03 1931-01-27 Winthrop Chem Co Substituted 1, 3-di-amino-2-propanols
US2605286A (en) * 1951-01-04 1952-07-29 Rohm & Haas Acetonyl alkylbenzyl dialkyl ammonium salts
US2876217A (en) * 1956-12-31 1959-03-03 Corn Products Co Starch ethers containing nitrogen and process for making the same

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3336196A (en) * 1964-07-06 1967-08-15 Bristol Myers Co Antidepressant compositions
US3366609A (en) * 1964-09-12 1968-01-30 Dunlop Rubber Co Polymerization of episulfides
US3475458A (en) * 1967-08-11 1969-10-28 Shell Oil Co Production of epoxy ammonium salts
WO1983000513A1 (en) * 1981-08-10 1983-02-17 Saingier, Jean New n-oxyranemethane n,n,n-trialkylammonium derivatives, preparation method and utilization thereof for the treatment of polyhydroxylated and polyamnated polymers
AT380878B (en) * 1981-08-10 1986-07-25 Gosse Filature METHOD FOR PRODUCING SALTS FROM DERIVATIVES OF N-OXIRANETHANE-N, N, N-TRIALKYLAMMONIUM

Similar Documents

Publication Publication Date Title
FI62821B (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC THERAPEUTIC HYDROXYSYROR
CA1155115A (en) Basic ethers, a process for their preparation and pharmaceutical compositions containing same
EP0047536B1 (en) Substituted propylamines
PL83097B1 (en)
DE69517433T2 (en) BENZOZYCLLOAL COMPOUNDS, THEIR PRODUCTION AND USE
US3287375A (en) Nu, nu-dimethyl-nu-(2, 3-epoxypropyl)-omicron-substituted benzylammonium salts
US4018830A (en) Phenylthioaralkylamines
NO146356B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE ALKANOLAMINE DERIVATIVES
HU191586B (en) Process for preparing new derivatives of pyridazine and pyrimidine
US2918401A (en) Treatment of nematodes with quaternary ammonium compounds
US4176193A (en) Therapeutic isobutyramides
US2862965A (en) Pharmaceutical compounds
US2648710A (en) Bis-quaternary salts of 1:10-bis-(dialkylamino)-5:6-dithia-decane
JPS6183147A (en) Novel aminoalcohol derivative and its preparation
US4451473A (en) 3,7-Diazabicyclo [3.3.1] nonanes having anti-arrhythmic activity
US3917600A (en) 2-(Benzofuran)-acetamidines
US2880209A (en) Piperazine quaternary salts having parasitical activity and method of making
US3378586A (en) Phenyl lower alkylthio-alkylamino acetanilide derivatives
US3071613A (en) N-(2, 2-dialkoxyethyl)-(halogenated-phenyl) alkylamines
US5055490A (en) Stereoisomers of benzonitrile derivatives, useful as cardiac arrhythmiac agents
US4044132A (en) Substituted piperazine derivative, its preparation and anorexia compositions containing it
US3728389A (en) Biologically active amidines and their preparation
US3336196A (en) Antidepressant compositions
US3718678A (en) 1-({60 -cyanomethylene-hydrazino)-phenoxy-3-aminopropan-2-ols
US3516990A (en) 13-alkyl-5alpha-gonanediyl-bis(n-alkyl-n-heterocyclic halides)